2 completed, 1 active not recruiting, 1 recruiting. 2 Phase 2, 2 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Active not recruiting 1, Completed 1 |
| Phase 3 | 2 | Active not recruiting 1, Recruiting 1 |
| Phase 1 | 1 | Completed 1 |
Follow Moderate-to-severe Chronic Plaque Psoriasis: new trials by email Literature Review of Moderate-to-severe Chronic Plaque Psoriasis trials Research Report on Moderate-to-severe Chronic Plaque Psoriasis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis Ponesimod - Moderate-to-severe Chronic Plaque Psoriasis | Phase 3 | Recruiting | Vanda Pharmaceuticals | 300 | 2026-02-17 | 2026-09-22 |
| A Study of Tildrakizumab in Pediatric Subjects With Chronic Plaque Psoriasis Tildrakizumab, Placebo, Etanercept - Moderate-to-severe Chronic Plaque Psoriasis | Phase 2 / Phase 3 | Active not recruiting | Sun Pharmaceutical Industries Limited | 135 | 2020-01-15 | 2026-04-15 |
| Multi-Dose Study of SHR-1314 in Subjects With Moderate-to-severe Plaque Psoriasis SHR-1314, Placebo - Moderate-to-severe Chronic Plaque Psoriasis | Phase 1 / Phase 2 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 211 | 2017-12-15 | 2023-08-08 |
| Study of Adalimumab (HUMIRA®) in Patients With Moderate to Severe Psoriasis (PS) in Spain (PROMISE) Moderate-to-severe Chronic Plaque Psoriasis | Completed | AbbVie (prior sponsor, Abbott) | 547 | 2010-02-01 | 2016-01-06 |
Psoriasis (2)
Skin Diseases (2) · Skin Diseases, Papulosquamous (2) · Skin and Connective Tissue Diseases (2)
Etanercept (1) · ponesimod (1) · tildrakizumab (1)
AbbVie (prior sponsor, Abbott) (1) · Jiangsu HengRui Medicine Co., Ltd. (1) · Sun Pharmaceutical Industries Limited (1) · Vanda Pharmaceuticals (1)
United States (3) · Australia (1) · China (1) · Hungary (1) · India (1) · Poland (1) · Slovakia (1) · Spain (1)
Cristina Sancho Sanchez, PharmD (1)